NCT05778864View on ClinicalTrials.gov

A Study of LY3473329 in Participants With Impaired and Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

September 6, 2024

Study Completion Date

September 6, 2024

Conditions
Renal Insufficiency
Interventions
DRUG

LY3473329

Administered orally.

Trial Locations (4)

32132

Velocity Clinical Research, New Smyrna Beach, Edgewater

32809

Orlando Clinical Research Center, Orlando

33417

Advanced Pharma CR, LLC, Miami

37920

Alliance for Multispecialty Research, LLC, Knoxville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY